Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, Pfizer Renew Metabolic Disease Research Collaboration

Premium

NEW YORK (GenomeWeb News) – KineMed this week announced the renewal of its non-exclusive research collaboration with Pfizer into metabolic disease, and type 2 diabetes in particular.

The collaboration was originally established in 2013 and calls for KineMed to use its dynamic proteomics technology platform to map the impact of potential drug candidates.

KineMed's technology uses wide-scale isotopic labeling and mass spectrometry to track protein activity kinetics, which can elucidate biological pathways and disease processes.

This marks the second renewal of the two firms' collaboration, following an initial renewal announced in March.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.